StocksMedium•8 October 2026•
1 min read
Argenx Shares Plunge 16% After Halting Sjögren’s Disease Drug Trial
Key Facts
1Argenx shares fell 16% following the announcement that it is halting a Phase 3 trial for a Sjögren’s disease treatment.
Argenx shares fell 16% following the announcement that it is halting a Phase 3 trial for a Sjögren’s disease treatment. Investing.com reported that the decision triggered a massive sell-off in the stock on October 8, 2026.
The sharp decline followed the company's move to stop the advanced clinical study, directly impacting its valuation and pipeline outlook. The stock was trading lower on October 8, 2026, as investors reacted to the termination of the late-stage trial.